

AKR1C3 Antibody

Rabbit mAb Catalog # AP92124

Product Information

Application WB, IF, FC, ICC, IP

Primary Accession P42330
Reactivity Human
Clonality Monoclonal

Other Names DD3; DDX; HA1753; HAKRB; HAKRe; HSD17B5; KIAA0119; hluPGFS;

IsotypeRabbit IgGHostRabbitCalculated MW36853

Additional Information

Dilution WB 1:500~1:1000 ICC/IF 1:50~1:200 IP 1:30 FC 1:50

Purification Affinity-chromatography

Immunogen A synthesized peptide derived from human AKR1C3

Description Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the

reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a

bi-directional 3-alpha-, 17-beta- and 20-alpha HSD.

Storage Condition and Buffer Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium

azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term.

Avoid freeze / thaw cycle.

Protein Information

Name AKR1C3

Function Cytosolic aldo-keto reductase that catalyzes the NADH and

NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone (PubMed:10622721, PubMed:11165022, PubMed:7650035, PubMed:9415401, PubMed:9927279). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed:11165022, PubMed:14672942). Acts preferentially as a 17- ketosteroid reductase and has the highest catalytic efficiency of the AKR1C enzyme for the reduction of delta4-androstenedione to form testosterone (PubMed:20036328). Reduces prostaglandin (PG) D2 to 11beta-prostaglandin F2, progesterone to 20alpha-hydroxyprogesterone and

estrone to 17beta-estradiol (PubMed: 10622721, PubMed: 10998348,

PubMed:<u>11165022</u>, PubMed:<u>15047184</u>, PubMed:<u>19010934</u>,

PubMed: 20036328). Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed: 10557352, PubMed: 10998348, PubMed: 11165022, PubMed: 14672942, PubMed: 7650035, PubMed: 9415401). Also displays retinaldehyde reductase activity toward 9-cis-retinal (PubMed: 21851338).


Cellular Location

Cytoplasm.

Tissue Location

Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. High expression in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate

Images



Western blot analysis of AKR1C3 expression in A549 cell lysate.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.